Drug Discovery Opinion

In total, around 200million people are thought to be infected hepatitis C virus (HCV). The current standard of care treatment for (HCV) infection is a combination of pegylated interferon, an immune modulator, and ribavirin, an antiviral drug. Interferon/ribavirin therapy is effective in only around 50% of patients with the most difficult-to-treat HCV, type 1. A number of new small molecule antiviral drugs are being developed, and Roche, Pharmasset and InterMune have recently announced the first clinical trial of an interferon-free combination of an HCV NS3/4A protease inhibitor, R7227, and an HCV NS5B polymerase inhibitor prodrug, R7128. Both the protease and polymerase are essential for viral replication and the new study, which will be carried out in Australia and New Zealand, will look at safety and combined antiviral activity of the two compounds in combination.

R7227, which is being developed in collaboration with InterMune, and R7128, which is being developed in collaboration with Pharmasset, have both already successfully completed studies in combination with pegylated interferon and ribavirin.

Bookmark It

Hide Sites

Related posts:

1. HCV NS5A Inhibitor Shows Early Promise in Clinic Hepatitis C virus (HCV) is a leading cause of liver disease and the current ‘standard of care’ treatment, a combination...
2. New (Host) Target for Treating HCV Hepatitis C virus (HCV) is one of the most important causes of chronic liver disease and infection can lead ultimately...
3. Enzyme Deficiency Protects from Ribavirin-Related Anaemia Some 200 million people worldwide are estimated to be infected with the hepatitis C virus (HCV) which can eventually lead...
4. Structure of Ebola Virus Protein Determined Ebola virus, named after a river in the Democratic Republic of the Congo where it was first identified, causes a...
5. Host Kinases Linked to HCV Infection Globally, around 200 million people are infected with Hepatitis C virus (HCV). Infection generally leads to chronic liver disease, albeit...

Related posts brought to you by Yet Another Related Posts Plugin.

 Email This Post

This entry was posted on Wednesday, November 19th, 2008 at 9:02 am and is filed under News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.